The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial

Table 1 Patients’ demographic and anthropometric characteristics in the curcumin and placebo groups

Variables	Curcumin group (N: 23)	Placebo group (N: 23)	P value
Male, n (%)	14 (60.9)	13 (56.5)	0.765^†
Female, n (%)	9 (39.1)	10 (43.5)	0.765^†
Married, n (%)	18 (78.3)	19 (82.6)	0.710^†
Age, years	43.74 ± 12.9	51.52 ± 13.8	0.056
Weight, kg	78.94 ± 12.9	73.39 ± 12	0.141
Height, cm	170.04 ± 9.7	165.34 ± 7.8	0.077
Body mass index (BMI), kg/m²	26.74 ± 3.9	26.35 ± 4.7	0.763
Diabetes, n (%)	7 (30.4)	5 (21.7)	0.502^†
Hypertension, n (%)	5 (21.7)	6 (26.1)	0.730^†
Heart diseases, n (%)	4 (17.4)	3 (13)	1^††
Academic education, n (%)	12 (52.2)	9 (39.1)	0.375^†
Drug usage, n (%)	13 (56.5)	16 (69.6)	0.359^†

Data are reported as mean ± standard deviation or frequency (percentage) as appropriate
^†P values were calculated using the chi-squared test
^††P values were calculated using the Fisher exact test
*P values were calculated using the two-sample T test

ISSN: 1745-6215